Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic…
News
Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from…
Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with…
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
Some 68 percent of Canadians would feel helpless if they or someone close to them received a blood cancer diagnosis, found a recent poll commissioned…
Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro…
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free…
